From the VentureWire story:
Investors in the Series C funding included new investors WavePoint Ventures and Johnson and Johnson Development Corp., as well as previous investors Technology Funding and individual investors.
The funding will be used for the development of Impres Medical’s device targeting abnormal uterine bleeding, which works by going into the bottom of the uterus and deactivating a patient’s menstrual period. This condition is also treated with endometrial ablation, hysterectomy or with prescription medication, mostly including birth control pills, according to [CEO Wally] Danielson.
The company’s otherwise bare-bones Web site describes the technique as an alternative to hysterectomy that can be performed as “a simple office procedure.”